Final answer:
The primary endpoint of the EMPA-RED Trial was the reduction in major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease.
Step-by-step explanation:
The primary endpoint of the EMPA-RED Trial was the reduction in major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease.
The trial aimed to evaluate the cardiovascular outcomes of empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, compared to placebo in this patient population.
Empagliflozin demonstrated a statistically significant reduction in MACE and cardiovascular death, leading to its approval for use in patients with type 2 diabetes and cardiovascular disease.